Abstract Nasopharyngeal carcinoma (NPC) has been shown to be a radio-and chemosensitive tumor and combined chemoradiotherapy is the standard of care for advanced-stage patients. Different chemotherapy strategies (neoadjuvant, concurrent, adjuvant) are incorporated with radiotherapy to enhance treatment outcome and each mode of combined therapy has advantages and disadvantages. There are many randomized clinical trials investigating the role of adding chemotherapy in NPC management. So far, concurrent and neoadjuvant chemotherapy are more frequently used for locoregionally advanced tumors. However, the current reality is that (1) distant failure is the most frequent site of relapse reported in all studies, (2) patients have already received neoadjuvant and/or concurrent chemotherapy, and (3) only some tumors recur after previous neoadjuvant/concurrent chemotherapy with radiotherapy. So, adjuvant chemotherapy is a reasonable timing to consolidate the treatment outcome for selected patients. Recently, several tumor markers can predict tumors with high probability of recurrence. Among these markers, plasma EBV DNA assay is a simple and reliable one in predicting prognosis. In this mini-review, I will focus on the role of adjuvant chemotherapy based on plasma EBV DNA load.
Introduction
Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. Because of the inherent anatomic constraints and a high degree of radiosensitivity, radiotherapy (RT) has been the primary treatment for NPC patients. NPC is also a chemosensitive tumor. Various modes of combined chemoradiotherapy have been used to treat NPC patients with advanced-stage diseases during recent 20 years. However, treatment outcome for locoregionally advanced NPC is still unsatisfactory. Table 1 lists survival outcome from some larger series with adequate follow-up [1] [2] [3] [4] [5] [6] [7] . The 5-year relapse/progression-free survival rates for patients with stage III and IV disease were 47-62 % and 30-44 %, respectively. The overall survival rates at 5 years were 55-80 % and 28-61 % in stage III and IV, respectively. These data indicate that there is much room for improvement.
Recent advances in cancer biology have developed many clinically useful biomarkers that can aid in risk grouping of patients with similar stage and guidance of optimal treatment for each patient, such as epidermal growth factor receptor mutations in non-small cell lung cancer, KRAS mutation in colorectal cancer, methylation status of the MGMT promoter in glioblastoma, etc. It is difficult to get adequate tumor specimens for biomarkers research in NPC because it is basically treated without surgery. Recently, cell-free circulating EBV DNA can be detected in plasma and serum of NPC patients and has been shown to hold promise as a reliable biomarker in the detection, monitoring, and prediction of outcome for NPC [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . This mini-review will focus on the role of adjuvant chemotherapy based on plasma EBV DNA load.
Patterns of failure
Information detailing treatment-failure patterns is important in designing new treatment protocols. Before 1990, larger series from endemic areas [18] [19] [20] [21] [22] [23] [24] and nonendemic regions [25] [26] [27] [28] [29] [30] reported that treatment failure was due to both a high rate of local recurrence (ranging from 10.2 % to 31.0 % in endemic areas and 26.0 % to 63.3 % in non-endemic regions) and distant metastasis (ranging from 24.0 % to 43.5 % in endemic areas and 12.7 % to 36.3 % in non-endemic regions). Since the transition from two-dimensional RT to 3D/IMRT-based RT, the failure of treatment for NPC predominantly has been due to distant metastasis. Table 2 summarizes the patterns of failure from several larger series for NPC patients treated with non-IMRT techniques [2, 3, 6, 7, [31] [32] [33] [34] [35] [36] . A total of 7,319 patients were collected from 8 reports; there were 1,100 (15.0 %) local recurrences, 403 (5.5 %) regional recurrences, and 1,666 (22.8 %) distant failures. In contrast, in the latest reports [31, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] ] the observed relapse rates in local, regional, and distant sites are substantially better, most likely due to improvements in RT and to greater use of combined chemotherapy. Table 3 presents data from 1826 patients in 12 studies and shows local, regional, and distant failures in 112 (6.1 %), 59 (3.4 %), and 218 (12.4 %) patients, respectively. Although the follow-up periods of these studies are too short to permit a definite conclusion, I believe that the higher locoregional control rate is achievable using modern radiation techniques alone for early-stage tumors and combined chemoradiotherapy for advanced-stage tumors. [2, 3, [5] [6] [7] 36] . Thus, patients with N3 or overall stage IV disease clearly are at greatest risk. NPC has been proven as an EBV-associated cancer for a long time. Evidences of (1) the presence of DNA, RNA, and proteins of EBV in almost all cancer cells of almost all tissue samples (primary and various metastatic sites) obtained from patients with NPC [48] [49] [50] , (2) tumor cells proved to be derived from a single EBV-infected cell [51] , and (3) high levels of EBV protein antibodies in newly found NPC patients [52] [53] [54] and in healthy individuals in whom NPC later developed [55, 56] suggested that EBV may serve as a marker for NPC. Recent development of the real-time quantitative polymerase chain reaction assay allows us to detect circulating EBV DNA fragments in most newly diagnosed NPCs [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . In addition, pEBV DNA is rarely detected in healthy people and long-term survivors of NPC without relapse [8, 14] . Lin et al. found a concordant decrease pattern of EBV DNA level in both primary tumor cells and plasma samples after neoadjuvant chemotherapy (NeoCT) along with consistent genotyping of EBV DNA between paired samples of plasma and primary tumor strongly suggesting that the circulating cell-free EBV DNA originates from the primary tumor [14] . The pretreatment pEBV DNA concentrations have been shown to correlate with the clinical stages of NPC [8, [14] [15] [16] . Ma et al. further analyzed the relationship between the pEBV DNA level with MRI-delineated tumor volume and with tumor metabolic activity by PET/CT scan and showed that circulating EBV DNA level reflects overall tumor load [57] . Furthermore, studies from endemic area [8] [9] [10] [11] [12] [13] [14] [15] [16] observed that (1) the pEBV DNA decreases to normal after treatment in patients with complete remission but remains elevated in patients with residual disease, (2) the pEBV DNA increases simultaneously or in advance of clinical tumor relapse, and (3) the level of the pEBV DNA can predict an individual patient's survival and prognosis. All data from high- incidence areas consistently illustrate that quantification of pEBV DNA is an ideal tumor marker for NPC. Recent studies from low-incidence countries also showed similar results [17, [58] [59] [60] . More importantly, pEBV DNA assay is a simple and hospital-based laboratory test with quantitative information.
Although the pre-treatment pEBV DNA load can detect high-risk tumors [8, [10] [11] [12] [13] [14] [15] [16] , post-treatment pEBV DNA levels also have prognostic importance and the post-treatment viral load dominates the effect of the pre-treatment load [11, [14] [15] [16] [17] . Chan et al. recruited 170 NPC patients who received a uniform RT protocol with/without chemotherapy. After a short follow-up (median 116 weeks), they observed that the 1-year progression-free survival rates for patients who had post-treatment viral load of less than 500 copies/mL versus more than 500 copies/mL were 93 % and 48 %, respectively [11] . Using a cutoff 04,000 copies/mL for pre-treatment pEBV DNA and a cutoff of 500 copies/mL for posttreatment pEBV DNA, they divided patients into four subgroups with 1-year survival rates of 32 % (high post and high pre), 50 % (high post and low pre), 84 % (low post and high pre), and 97 % (low post and low pre). By retrospective measurement of plasma samples from 152 NPC patients who received a uniform protocol of concurrent chemoradiotherapy (CCRT) and a median follow-up of 78 months, Lin et al. could stratify patients into 3 different groups with 5-year overall survival and relapse-free survival rates of 87.2 %, 71.0 %, 38.7 % (P <0.0001), and 85.6 %, 75.9 %, and 26.9 % (P<0.0001), respectively, by combined pretreatment and post-treatment pEBV DNA levels [15] . In another group of 210 NPC patients prospectively treated by NeoCT+RT with a minimum follow-up of 6 years, Lin et al. observed similar results (unpublished data). The 5-year overall survival (59.2 % vs. 86.0 %, P00.0003) and relapse-free survival (56.5 % vs. 79.3 %, P<0.0001) were significantly lower in patients with pretreatment pEBV DNA ≥1,500 copies/mL than in those with pEBV DNA <1,500 copies/mL. Patients with persistently detectable pEBV DNA 1 week after NeoCT-RT had significant worse overall (33.3 % vs. 79.4 %, P< 0.0001) and relapse-free survivals (23.3 % vs. 75.6 %, P< 0.0001) than those with undetectable pEBV DNA. Le et al. from the Stanford University reported a significant correlation between post-treatment pEBV DNA levels and freedomfrom-relapse or overall survival in 58 newly diagnosed NPC patients [17] . The 2-year freedom-from-relapse and overall survival rates were 92 % and 94 % for patients with undetectable and 37 % and 55 % for those with persistently detectable post-treatment pEBV DNA levels (P<0.0001 and P<0.002). Hou et al. collected 69 NPC patients and observed that patients with post-treatment detectable pEBV DNA had worse 5-year metastasis-free survival (50.0 % vs. 91.2 %, P<0.001) and overall survival (50.0 % vs. 91.2 %, P<0.001) than those with undetectable pEBV DNA [16] . In summary, patients with persistently detectable post-treatment pEBV DNA or high pre-treatment pEBV DNA load represent the subgroup having the highest risk.
Search for a more effective treatment protocol Combined chemoradiotherapy has been accepted by most oncologists as the standard treatment of advanced NPC. There is still great controversy, however, regarding the optimal drugs, timing, dosage, and duration of chemotherapy. In general, there are three different ways to incorporate chemotherapy into a curative course of RT: NeoCT, concurrent chemotherapy, and adjuvant chemotherapy (AdjCT) that are delivered before, during, and after RT. Each mode of combined therapy has advantages and disadvantages and has been extensively investigated during past years. In brief speaking, the major flaws of NeoCT are triggering of accelerated repopulation and cross-resistance during subsequent RT. The dose intensity of concurrent chemotherapy that can be delivered safely during 7-8 weeks RT is usually lower than in NeoCT or AdjCT setting. This may compromise its efficacy in eradication of micrometastasis. Poor compliance and compromised blood supply are the two major problems of AdjCT.
To the best of my knowledge, there are 21 randomized clinical trials investigating the role of adding chemotherapy in NPC treatment . Unfortunately, the results are somewhat confusing at first glance. The most important trial is the Intergroup study 0099 published in 1998 [64] . Using concurrent cisplatin (P) 100 mg/m 2 every 3 weeks during RT followed by 3 cycles post-radiation AdjCT of cisplatin 80 mg/m 2 day 1+5-fluorouracil (F) 1,000 mg/m 2 days 1-4, Al-Sarraf et al. reported that CCRT+AdjCT is superior to RT alone. Of 193 patients with 1987 AJCC/UICC stage III-IV (re-staged to II-IVB by 1997 AJCC staging system) registered, 147 were eligible for analysis. The 3-year progression-free survival (69 % vs. 24 %, P<0.001) and overall survival (78 % vs. 47 %, P00.005) favored for the combined chemoradiotherapy group. Since then, this regimen has become the standard of care for advanced NPC patients. Using the same design (CCRT+AdjCT vs. RT alone), same chemotherapeutic agents and same/similar chemotherapy dose intensity, four subsequent trials [72, 73, 75, 76] from endemic areas (one from Singapore, two from Hong Kong, one from China) generally have supported the results of the Intergroup study. Table 4 shows some pertinent parameters and outcome of these trials with updated data [81] [82] [83] [84] [85] . The overall survival and progression-free/disease-free/failure-free survival rates are significant higher in the CCRT+AdjCT arm (all P<0.05). In my view, the major treatment is RT and both concurrent and adjuvant chemotherapy are integral parts of the protocol. It is difficulty and unnecessary to differentiate which parts of chemotherapy contribute more to the outcome. There were three trials [67, 70, 74] using CCRT vs. RT alone with different concurrent chemotherapy regimen and all results favored CCRT (Table 5) . Similarly, another 3 trials [63, 65, 66, 86, 87] using NeoCT+RT vs. RT alone with different NeoCT regimens and one phase II randomized trial [77] using NeoCT+ CCRT vs. CCRT also demonstrated statistically significant or borderline significant effects favoring the arm containing NeoCT (Table 6 ). One trial [68] used the design of RT+ AdjCT vs. RT alone by the Taiwan Cooperative Oncology Group (TCOG). The overall survival was not significantly different (most likely due to more unexplained non-cancer deaths in the combined treatment group); however, AdjCT reduced distant metastasis rate from 36.4 % in the RT alone to 19.5 % in the combined treatment arm (P00.03).
In preparing this mini-review, I did not analyze some trials for a variety of reasons including chemotherapy regimen or dosage [61, 62, 69] , small sample size [62, 69] , inclusion of early stage tumors [61, 69, 89] , and a 2×2 trial design [71] . Three latest trials, published in 2012 using NeoCT+CCRT vs. CCRT [78] , CCRT+AdjCT vs. CCRT [79] , and NeoCT-RT + AdjCT vs. CCRT + AdjCT [80] design, all showed no significant difference in both arms.
Based on above discussion, I believe that adding chemotherapy (no matter what kind-concurrent, neoadjuvant, or adjuvant) to RT will enhance the treatment efficacy beyond RT alone. However, we should not forget that all trials reported substantially increased toxicity associated with combined treatment.
The role of post-radiation adjuvant chemotherapy in NPC
Who needs adjuvant chemotherapy?
The major goal of AdjCT is to reduce subsequent appearance of distant metastasis. But, not all advanced NPC patients need AdjCT. We should remember that unnecessary or ineffective adjuvant therapy is frequently used. For example, if we treat all patients with a 50 % subsequent distant failure rate and our regimen has a CCRT concurrent chemoradiotherapy, AdjCT adjuvant chemotherapy, RT radiotherapy, OS overall survival, PFS progression-free survival, DFS disease-free survival, FFR failure-free survival, y year, m month, SYSU Sun Yat-sen University, HK Hong Kong, P cisplatin, F fluorouracil, q3w every 3 weeks, qw every week, d day, q4w every 4 weeks a P100 indicates cisplatin 100 mg/m 2 ; F1000d1-4 indicates fluorouracil 1000 mg/m 2 days 1-4, etc. When to start adjuvant chemotherapy?
Most randomized trials have begun AdjCT 3-4 weeks after completion of RT. However, this time point may not be the best one. NPC patients often are debilitated that soon after a course of curative RT with/without neoadjuvant and/or concurrent chemotherapy. The percentage of patients who could tolerate all planned AdjCT every 4 weeks was between 55 % and 76 %, based on the Intergroup study and its reported modifications [64, 72, 73, 75, 76] . Two recent RTOG trials (0225 and 0615) reported only 46 % and 48 % of patients completed the 3 cycles of AdjCT [42, 90] . In a phase II study using weekly a schedule of PF plus leucovorin (PFL) and starting about 12 weeks after finishing RT, Lin et al. observed that 87.8 % (36/41) of patients could complete 18 weekly cycles of AdjCT [91] . Using a different dose of weekly PFL starting 4 weeks after finishing RT, Chi et al. reported a 52 % compliance rate [68] . Based on the above discussion, it appears that it is the starting date, not the schedule/dosage of AdjCT that determines a patient's compliance. Moreover, there is no evidence to show that moving the start of AdjCT from 3 to 4 weeks to 12 weeks had negative impact on disease control or survival. Although the optimal starting point for AdjCT is unknown at present and should be studied further in the future, the data suggest that starting AdjCT 12 weeks after finishing RT may be preferable to the current general practice of 4 to 6 weeks.
What regimens should be used?
PF is still the most frequently used regimen for AdjCT of NPC but the conventional schedule (cisplatin around 75-100 mg/m 2 on day 1 plus 5-FU around 4,000 mg/m 2 divided in 4-5 days continuous infusion, repeated every 3-4 weeks) has significant acute toxicity. The reported rates of grade 3/4 mucositis and [91] . They found that 26.8 % (11/41) of the patients getting PFL and 47.7 % (42/88) patients who did not get AdjCT developed distant metastasis (P00.0247). The 5-year metastasis-free survival rates were 71.9 % for the PFL group compared with 48.4 % for no AdjCT patients (P0 0.0187) and the overall survival benefit nearly reached statistically significant (53.7 % vs. 38.3 %, P00.0666). No mucositis was observed and grade 3/4 leucopenia, anemia, thrombocytopenia, and vomiting were noted in 7.3 %, 2.4 %, 2.4 %, and 2.4 % cycles. A recent combined analysis of the pooled data from 441 patients with stage III/IV disease treated in the Hong Kong NPC-9901 and NPC-9902 trials showed that the dose of 5-FU during AdjCT was significantly associated with the distant failure-free rate by multivariate analysis [85] . The 5-year distant failure-free rates for patients who received 0-1, 2, and 3 adjuvant cycles were 68 %, 78 %, and 77 %, respectively (P00.063).
There is no other regimen reported to be as effective in adjuvant setting for NPC as PF. Other regimens that have activity in the neoadjuvant [63, 65, 66, 77, 78, [92] [93] [94] or salvage setting [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] , of course, can be considered for the adjuvant phase in future trials with some modifications, such as docetaxel [77, [93] [94] [95] [96] , paclitaxel [78, [102] [103] [104] [105] , gemcitabine [105] [106] [107] [108] [109] [110] , mitomycin C [92, 97, 100] , epirubicin [63, 92, [99] [100] [101] , bleomycin [63, 66, 98, 99, 101] , and vinorelbine [110] . Recently the RTOG 0615 trial reported that the addition of concurrent and adjuvant targeted therapy (bevacizumab 15 mg/m 2 per cycle) to standard chemoradiotherapy for advanced NPC is feasible and might delay the progression of subclinical distant disease [90] .
Conclusions
AdjCT remains a part of the standard of care for advanced stage NPC; however, it may not always be necessary. Future AdjCT trials should be confined to high risk tumors using some combination of pEBV load and/or high clinical stage to better select appropriate candidates. A phase III randomized trial based on post-radiation residual pEBV DNA load has been ongoing in Hong Kong and similar trials likely will be started by the RTOG and TCOG soon.
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